Uncategorized

Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth

Published

on

Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines like Zepbound, Mounjaro and Taltz.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version